Target c-Myc to treat pancreatic cancer
M Ala - Cancer biology & therapy, 2022 - Taylor & Francis
ABSTRACT C-Myc overexpression is a common finding in pancreatic cancer and predicts
the aggressive behavior of cancer cells. It binds to the promoter of different genes, thereby …
the aggressive behavior of cancer cells. It binds to the promoter of different genes, thereby …
Regulation of pancreatic cancer therapy resistance by chemokines
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by
high resistance and poor response to chemotherapy. In addition, the poorly immunogenic …
high resistance and poor response to chemotherapy. In addition, the poorly immunogenic …
MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition
MR Silvis, D Silva, R Rohweder, S Schuman… - Journal of Experimental …, 2023 - rupress.org
Pharmacological inhibition of KRAS> RAF> MEK1/2> ERK1/2 signaling has provided no
clinical benefit to patients with pancreatic ductal adenocarcinoma (PDAC). Interestingly …
clinical benefit to patients with pancreatic ductal adenocarcinoma (PDAC). Interestingly …
High‐throughput, microscope‐based sorting to dissect cellular heterogeneity
N Hasle, A Cooke, S Srivatsan, H Huang… - Molecular Systems …, 2020 - embopress.org
Microscopy is a powerful tool for characterizing complex cellular phenotypes, but linking
these phenotypes to genotype or RNA expression at scale remains challenging. Here, we …
these phenotypes to genotype or RNA expression at scale remains challenging. Here, we …
Potential role of exosomes in the chemoresistance to gemcitabine and nab-paclitaxel in pancreatic cancer
A Comandatore, B Immordino, R Balsano, M Capula… - Diagnostics, 2022 - mdpi.com
In recent years, a growing number of studies have evaluated the role of exosomes in
pancreatic ductal adenocarcinoma cancer (PDAC) demonstrating their involvement in a …
pancreatic ductal adenocarcinoma cancer (PDAC) demonstrating their involvement in a …
[HTML][HTML] Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor prognosis and
rising global deaths. Late diagnosis, due to absent early symptoms and biomarkers, limits …
rising global deaths. Late diagnosis, due to absent early symptoms and biomarkers, limits …
Assessment of spatial transcriptomics for oncology discovery
A Lyubetskaya, B Rabe, A Fisher, A Lewin… - Cell Reports …, 2022 - cell.com
Tumor heterogeneity is a major challenge for oncology drug discovery and development.
Understanding of the spatial tumor landscape is key to identifying new targets and impactful …
Understanding of the spatial tumor landscape is key to identifying new targets and impactful …
Oncogenic RAS promotes MYC protein stability by upregulating the expression of the inhibitor of apoptosis protein family member Survivin
The small GTPase KRAS is frequently mutated in pancreatic cancer and its cooperation with
the transcription factor MYC is essential for malignant transformation. The key to oncogenic …
the transcription factor MYC is essential for malignant transformation. The key to oncogenic …
Degradation of DRAK1 by CUL3/SPOP E3 Ubiquitin ligase promotes tumor growth of paclitaxel-resistant cervical cancer cells
Despite favorable responses to initial chemotherapy, drug resistance is a major cause
limiting chemotherapeutic efficacy in many advanced cancers. However, mechanisms that …
limiting chemotherapeutic efficacy in many advanced cancers. However, mechanisms that …
Zebrafish xenografts for drug discovery and personalized medicine
Cancer is the second leading cause of death in the world. Given that cancer is a highly
individualized disease, predicting the best chemotherapeutic treatment for individual …
individualized disease, predicting the best chemotherapeutic treatment for individual …